H
Human Longevity
A genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived
About Human Longevity
In 2013, Human Longevity Inc. was founded by visionary leaders Craig Venter, Peter Diamandis, and Robert Hariri. The company embarked on a mission to revolutionize healthcare by leveraging genomics and data-driven insights to enhance human lifespan and healthspan.
Read full description
Human Longevity aimed to build the world's most comprehensive database of human genotypes and phenotypes, integrating advanced technology to predict and prevent diseases. This ambitious goal attracted significant attention and investment, leading to a major funding round in 2014, which raised $70 million. This capital infusion was pivotal in accelerating their research and development efforts.
Despite the initial excitement and potential, Human Longevity faced challenges in scaling its operations and achieving its lofty objectives. The company underwent several leadership changes and strategic pivots to adapt to the evolving landscape of personalized medicine.
In 2017, Human Longevity made headlines with a substantial $220 million Series B funding round, underscoring investor confidence in its vision. However, the journey was not without hurdles, as the company grappled with competition and the complexities of commercializing genomic data.
Today, Human Longevity continues to push the boundaries of what's possible in genomics and personalized healthcare, striving to fulfill its promise of extending healthy human life. The company's story is a testament to the challenges and triumphs of pioneering innovation in the biotech industry.
At a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- San Diego, United States
- Employees
- 80
- Open positions
- 9
- Dealroom signal
- 74.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Risk Management, Biotechnology, Oncology, DNA, Genetics and genomics
- Technology
- Artificial Intelligence, Big Data, Deep Tech, Machine Learning, Computer Vision
- Business model
- SaaS
- Client focus
- b2b
- Investment activity
- 2 companies, latest Jun 2020
- Capital deployed
- $259M
- Preferred round
- EARLY VC
Latest news
Press, funding announcements and product moves mentioning Human Longevity.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Aug 2024 | $40M | $159M | Panacea Venture · TVM Capital Healthcare · Emerging Technology Partners Biomedical | ↗ |
| SERIES COther financing | Nov 2019 | $30M | $120M | ETP Ventures | — |
Growth signals
Latest recorded traffic for Human Longevity is 27K monthly website visits, up 50% over the last three months. Human Longevity's team declined 1.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Floré by Sun GenomicsSan Diego, United StatesA microbiome health company focused on curing dysbiosis through personalized probiotics
$35Mvaluation
CelularityFlorham Park, United StatesClinical-stage biotechnology company productizing allogeneic cells and tissues derived from the postpartum placenta
$89Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Illumina
Bryan Johnson
Threshold Ventures
Celgene
GE Ventures
StartUp Health
Amino Capital
Series B and later4 investors entered at this stage
- EVETP Ventures
TVM Capital Healthcare
Panacea Venture- EBEmerging Technology Partners Biomedical
Other known investors1 additional known investor
J. Craig Venter Institute
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Human Longevity on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Human Longevity’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.